more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$318.02 USD

+0.10 (0.03%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $318.06 +0.04 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

Bottom 40% (149 out of 250)

Industry: Medical - Dental Supplies

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

SmileDirectClub (SDC) Moves up on New Strategic Actions

by Zacks Equity Research Published on January 25,2022

SmileDirectClub's (SDC) new strategic actions are focused on supporting the key growth initiatives that will generate the highest return on investment.

Here's Why You Should Add LabCorp (LH) to Your Portfolio Now

by Zacks Equity Research Published on January 24,2022

Investors are optimistic about LabCorp (LH) backed by increased COVID-19 testing demand and development in high-growth areas.

Quest Diagnostics (DGX) Rides on Test Sales, Base Volume Gain

by Zacks Equity Research Published on January 04,2022

Quest Diagnostics (DGX) continues to benefit from rapidly increasing molecular diagnostic testing volumes, driven by the massive spread of the new COVID-19 variant.

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research Published on January 04,2022

Investors are optimistic about Hologic (HOLX) given the strength in the diagnostics business and notable acquisition deals.

Here's Why You Should Hold on to Myriad Genetics (MYGN) for Now

by Zacks Equity Research Published on January 04,2022

Investors are optimistic about Myriad Genetics (MYGN), given robust volume growth for GeneSight and prenatal testing.

Phirbo's (PAHC) Rising Costs, Currency Headwind Ail Growth

by Zacks Equity Research Published on January 03,2022

Though Phirbo (PAHC) has raised prices on selective products, these increases do not fully compensate for the higher cost of freight and labor materials.

Here's Why You Should Hold on to National Vision (EYE) for Now

by Zacks Equity Research Published on January 03,2022

Investors are optimistic about National Vision (EYE), given new store growth for America's Best and Eyeglass World brands.

Here's Why You Should Hold on to Globus Medical (GMED) for Now

by Zacks Equity Research Published on January 03,2022

Investors are optimistic about Globus Medical (GMED), backed by strength in the Enabling Technologies arm and ExcelsiusGPS platforms.

Here's Why You Should Invest in Abbott (ABT) Stock Right Now

by Zacks Equity Research Published on December 31,2021

Riding on current business growth and bullish near-term prospects, Abbott (ABT) is worth investing in for now.

Thermo Fisher (TMO) Hits a 52-Week High: What's Driving It?

by Zacks Equity Research Published on December 31,2021

Strength in end markets and significant contribution from COVID-response related revenues are driving Thermo Fisher's (TMO) top line.

Omnicell (OMCL) Closes ReCept Holdings Acquisition Deal

by Zacks Equity Research Published on December 30,2021

Omnicell's (OMCL) completed buyout of the renowned specialty pharmacy management services provider is likely to bolster its Advanced Services offering.

Neogen (NEOG) Q2 Earnings Lag Estimates, Revenues Surpass

by Zacks Equity Research Published on December 29,2021

Robust segmental performance and contributions from StandGuard & Soleris product lines drove the top line for Neogen (NEOG) in the second quarter of fiscal 2022.